Remmington Enterprises (RMMG) 10-Q 12 Dec 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Oct. 31, 2014	Dec. 01, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Altovida Inc.	'
Entity Central Index Key	'0001529293	'
Document Type	'10-Q	'
Document Period End Date	31-Oct-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--07-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	77,650,166
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Oct. 31, 2014	Jul. 31, 2014
Current assets	'	'
Cash	$33,447	$210,399
Accounts receivable	50,298	44,508
Prepaid and deposits	17,273	3,381
Inventory	46,806	49,718
Other current assets	13,270	57,402
Total current assets	161,094	365,408
Equipment, net of accumulated depreciation of $1,346 and $353, respectively	20,523	20,141
Total assets	181,617	385,549
Current liabilities	'	'
Accounts payable and accrued liabilities	386,668	344,995
Total current liabilities	386,668	344,995
Long term liabilities:	'	'
Note payable	445,000	445,000
Total long-term liabilities	445,000	445,000
Total liabilities	831,668	789,995
Stockholders (deficit)	'	'
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of October 31, 2014 and July 31, 2014, respectively	'	'
Common stock, $0.001 par value; 90,000,000 shares authorized; 77,650,166 and 89,930,166 issued and outstanding at October 31, 2014 and July 31, 2014, respectively	77,650	89,930
Subscription receivable	-62,300	-74,580
Additional paid in capital	364,684	364,684
Other comprehensive income	73,392	-10,958
Accumulated (deficit)	-1,103,477	-773,522
Total stockholders (deficit)	-650,051	-404,446
Total liabilities and stockholders deficit	$181,617	$385,549

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet (Parenthetical) (USD $)	Oct. 31, 2014	Jul. 31, 2014
Statement of Financial Position [Abstract]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	0	0
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Issued	77,650,166	89,930,166
Accumulated depreciation	$1,346	$353

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (USD $)	3 Months Ended	11 Months Ended
	Oct. 31, 2014	Oct. 31, 2014
Revenue	'	'
Sales income	$78,952	$143,865
Cost of sales	38,599	86,067
Gross profit	40,353	57,798
Operating expenses	'	'
General and administrative	23,610	112,663
Professional fees	46,144	301,433
Rent expense	30,988	156,380
Research and development	77,907	110,891
Salaries and wages	138,335	436,681
Total operating expenses	316,984	1,118,048
(Loss) from operations	-276,631	-1,060,250
Other income (expense)	'	'
Interest expense	-6,675	-12,943
Gain on forgiveness of debt	'	24,000
(Loss) on foreign currency transactions	-46,649	-54,284
Total other income (expense)	-53,324	-43,227
Net loss	($329,955)	($1,103,477)
Net loss per common share - Basic and diluted	$0	($0.05)
Weighted average shares outstanding - Basic and diluted	84,872,087	22,361,319

Consolidated_Statement_of_Othe

Consolidated Statement of Other Comprehensive (Loss) (USD $)	11 Months Ended	12 Months Ended
	Oct. 31, 2014	Jul. 31, 2014
Consolidated Statement Of Other Comprehensive Loss	'	'
Net (loss)	($1,103,477)	'
Foreign currency translation	84,350	'
Total comprehensive (loss)	($1,030,085)	($784,480)

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	3 Months Ended	11 Months Ended
	Oct. 31, 2014	Oct. 31, 2014
Cash flows from operating activities	'	'
Net (loss)	($329,955)	($1,103,477)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Depreciation	993	1,346
Gain on forgiveness of debt	'	-24,000
Loss on foreign currency transactions	46,649	54,284
Changes in operating assets and liabilities	'	'
(Increase) in accounts receivable	-5,790	-50,298
(Increase) in inventory	2,912	-46,806
(Increase) in prepaid expenses	-13,892	-17,273
(Increase) decrease in other assets	44,132	-13,270
Increase in accounts payable and accrued liabilities	79,374	366,806
Net cash used in operating activities	-175,577	-832,688
Cash flows from investing activities	'	'
Purchase of fixed assets	-1,375	-21,865
Net cash provided by inventing activities	-1,375	-21,865
Cash flows from financing activities	'	'
Proceeds from cash advances	'	50,000
Proceeds from loans payable	'	419,000
Proceeds from the sale of common stock	'	419,000
Net cash provided by financing activities	'	888,000
Net change in cash	-176,952	33,447
Cash at beginning of period	210,399	'
Cash at end of period	33,447	33,447
Supplemental cash flow Information:	'	'
Cash paid for interest	'	'
Cash paid for income taxes	'	'
Supplemental disclosure of non-cash investing and financing activities:	'	'
Accounts payable and accrued liabilities assumed through acquisition	'	$46,915

Nature_of_Business_and_Summary

Nature of Business and Summary of Significant Accounting Policies	3 Months Ended
	Oct. 31, 2014
Accounting Policies [Abstract]	'
NATURE OF BUSINESS and Summary of Significant Accounting Policies	'
	Nature of Operations
	Altovida, Inc. (the "Company") was originally incorporated under the laws of the State of Nevada on July 15, 2011 as Remmington Enterprises, Inc. On May 02 2014, Remmington Enterprises, Inc. acquired Altovida Biosciences Ltd (formerly Mitovie Pharma Europe Ltd) and changed its business focus from the mining activities to the pharmaceutical industry. Following the acquisition, the Company amended its articles of incorporation to change its name from Remmington Enterprises, Inc. to Altovida, Inc. on October 29, 2014.
	Basis of Presentation
	The condensed interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.
	These statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these interim financial statements be read in conjunction with the financial statements of the Company for the period ended July 31, 2014 and notes thereto included in the Company's Form 10-K. The Company follows the same accounting policies in the preparation of interim reports.
	Results of operations for the interim periods are not indicative of annual results.
	The Company has adopted a July 31 year end.
	Principles of consolidation
	The consolidated financial statements include the accounts of Altovida, Inc. and Altovida Biosciences Ltd. All significant intercompany balances and transactions have been eliminated. Altovida, Inc. and Altovida Biosciences Ltd will be collectively referred herein to as the “Company”.
	Use of Estimates
	The preparation of financial statements in accordance with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to stock-based compensation, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
	Cash and Cash Equivalents
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.  At October 31, 2014, the Company had $33,447 in cash and no cash equivalents.
	Property and Equipment
	Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:
	Equipment 3-5 years
	Furniture 7 years
	The Company reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment there were no impairments needed as of October 31, 2014.
	Inventory
	Inventories consist of merchandise held for sale in the ordinary course of business, including cost of freight and other miscellaneous acquisition costs, and are stated at the lower of cost, or market value determined on the first-in-first-out basis. The Company records a write-down for inventories, which have become obsolete or are in excess of anticipated demand or net realizable value. The Company performs a detailed review of inventory each period that considers multiple factors including demand forecasts, market conditions, product life cycle status, product development plans and current sales levels. If future demand or market conditions for the Company’s products are less favorable than forecasted or if unforeseen changes negatively affect the utility of the Company’s inventory, it may be required to record additional write-downs, which would negatively affect gross margins in the period when the write-downs are recorded. If actual market conditions are more favorable, the Company may have higher gross margins when products incorporating inventory that were previously written down are sold.
	Fair Value of Financial Instruments
	Financial instruments consist of cash, inventory, prepaid expenses, accounts payable, and notes payable. Recorded values of these instruments approximate their fair values due to the short-term maturities of such instruments. Recorded values for notes payable and related liabilities approximate fair values, since their stated or imputed interest rates are commensurate with prevailing market rates for similar obligations.
	Earnings (Loss) Per Share
	The Company reports earnings (loss) per share in accordance with ASC Topic 260-10. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of October 31, 2014, there were no potential common shares underlying warrants or options.
	Revenue Recognition
	The Company recognized revenue at point of sale of product utilizing the following general revenue recognition criteria: 1) sales order received, and; 2) the price to the buyer is fixed or determinable; and 3) good have been shipped; and 4) collectability is reasonably assured.
	Income Taxes
	Income taxes are accounted for under the asset and liability method in accordance with ASC Topic 740-10. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When it is considered to be more likely than not that a deferred tax asset will not be realized, a valuation allowance is provided for the excess.
	Foreign Currency
	The Company accounts for foreign currency in accordance with ASC Topic 830 “Foreign Currency” whereby the local currency is the functional currency. Assets and liabilities of the Company’s foreign locations are translated to reporting currency at the rate of exchange existing at the balance sheet date. Income statement amounts are translated at a weighted average monthly exchange rate for each reporting period. The cumulative translation adjustments resulting from changes in exchange rates are included in the consolidated balance sheet as “Other comprehensive income”, a separate component of stockholders’ equity. Transaction gains and losses are included in the consolidated statement of operations. As of October 31, 2014, the Company recorded $84,350 in translation gains related to foreign currency translation.
	New Accounting Standards
	On June 10, 2014, the Financial Accounting Standards Board (FASB) issued a new accounting statement that reduces some of disclosures and reporting requirements for development stage companies. The change will be in effect for the interim and annual periods beginning after December 15, 2014. As of such date, among other things development stage entities will no longer be required to report inception-to-date information. The company has elected early adoption of this pronouncement and will no longer being reporting inception-to-date information.
	There are no other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Going_Concern

Going Concern	3 Months Ended
	Oct. 31, 2014
Notes to Financial Statements	'
Going Concern	'
	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company recorded a net loss of $329,995 for the period of August 01, 2014 to October 31, 2014. These conditions give rise to doubt about the Company’s ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional financing or sale of its common stock as may be required and ultimately to attain profitability per the current business plan.

Business_Combination

Business Combination	3 Months Ended
	Oct. 31, 2014
Business Combinations [Abstract]	'
Business Combination	'
	On May 2, 2014, the Company completed its acquisition of Altovida Biosciences, Ltd. (“Altovida”). In accordance with the terms of the Exchange Agreement, the Company issued 12,280,000 shares of its common stock to the shareholders of Altovida in exchange for all the outstanding stock of Altovida. Due to the change in control and form of consideration given, the transaction is being accounted for as a recapitalization of Altovida. Whereby Altovida is the accounting acquirer and the Company is the legal acquirer. Accordingly, it is the historic financial statements of Altovida retroactively restated giving effect to the accounting recapitalization. There were 15,505,000 shares of the Company’s common stock outstanding before giving effect to the stock issuances in the exchange. Immediately following the exchange, the Company’s majority shareholder cancelled its 12,050,000 shares. In connection with the Share Exchange Agreement, the Company entered into a Lock-Up Agreement with the acquiring shareholders whereby the Company and the shareholders agree to a one year prohibition on the sales or transfers of common stock held by the shareholders.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Oct. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Services Agreements
	On May 2, 2014, the Company appointed three officers of Altovida as officers and directors of the Company and assumed liabilities related to previously issued compensation agreements. Pursuant to the original agreements, effective as of March 1, 2014 provide for annual compensation to each executive of approximately $167,110 (£100,000) and standard employee benefits subject to a probationary period of six-months. The term of the agreement is indefinite but may be cancelled with six month written notice by either party.

Notes_Payable

Notes Payable	3 Months Ended
	Oct. 31, 2014
Debt Disclosure [Abstract]	'
Notes payable	'
	On May 1, 2014, the Company entered into a Replacement Promissory Note in the amount of $419,000 with Knight Financial, Ltd. (“Knight”) in contemplation of its May 2, 2014 Share Exchange Agreement.
	Whereas, Altovida previously issued a Senior Secured Bridge Loan in the principal amount of $81,421 and received a cash advance in the amount of $50,000 of which Knight agreed to forgive $24,000. The new note was issued by the Company for the purpose of reflecting all amounts owed to Knight and to restate the terms of the aforementioned security agreement. The replacement note bears interest at a rate of 6% per annum, matures on May 1, 2018 and is secured by all the assets of the Company.
	As of October 31, 2014, the unpaid principle balance totaled $445,000 and accrued interest amounted to $12,943. Additionally the Company recorded interest expense for the three month period in the amount of $6,675.

Stockholders_Deficit

Stockholders (Deficit)	3 Months Ended
	Oct. 31, 2014
Equity [Abstract]	'
Stockholders (Deficit)	'
	We are authorized to issue up to 90,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock. The Preferred Stock may be issued in one or more series, with all rights and preferences being determined by the board of directors.
	Preferred Stock
	The voting rights, rate of dividends preference in relation to other classes or series, and rights in the event of liquidation related to shares of Preferred Stock of any series are determined by the board of directors and may vary from time to time.
	Common Stock
	Holders of common stock have voting rights equal to one vote for each share of Common Stock held and are entitled to receive dividends when, and if declared by the board of directors subject to the rights of any Preferred Stock having preference as to dividends. In the event of liquidation or dissolution, subject to the rights of Preferred Stock holders are entitled to share ratably in the Corporations assets. Holders of Common Stock do not have conversion, redemption or preemptive rights.
	On May 2, 2014, the Company sold Knight Financial, Ltd. 69,833 common shares at a price of $6 per share, for a total proceeds of $419,000. As of October 31, 2014 the shares were unissued.
	On June 20, 2014, the Company issued 37,325,083 shares to its CEO, Michael Richard Hawthorne, and 37,325,083 to its Executive Chairman, Vinod Kaushal at $0.001 per share.
	On September 23, 2014, the Company cancelled 12,280,000 shares of its common stock of which 5,800,000 related to the issuance on June 20, 2014 to the Company’s CEO, Michael Hawthorne, and 5,800,000 related to the issuance on June 20, 2014 to its Executive Chairman, Vinod Kaushal.
	The $64,650 due for the adjusted share balance due from related parties has not been paid as of October 31, 2014 and remains a subscription receivable.

Subsequent_Events

Subsequent Events	3 Months Ended
	Oct. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	In accordance with ASC 855, management evaluated all activity of the Company through the issue date of the financial statements and concluded that no subsequent events have occurred that would require recognition or disclosure in the financial statements.

Nature_of_Business_and_Summary1

Nature of Business and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Oct. 31, 2014
Accounting Policies [Abstract]	'
Nature of Operations	'
	Altovida, Inc. (the "Company") was originally incorporated under the laws of the State of Nevada on July 15, 2011 as Remmington Enterprises, Inc. On May 02 2014, Remmington Enterprises, Inc. acquired Altovida Biosciences Ltd (formerly Mitovie Pharma Europe Ltd) and changed its business focus from the mining activities to the pharmaceutical industry. Following the acquisition, the Company amended its articles of incorporation to change its name from Remmington Enterprises, Inc. to Altovida, Inc. on October 29, 2014.
Basis of Presentation	'
	The condensed interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.
	These statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these interim financial statements be read in conjunction with the financial statements of the Company for the period ended July 31, 2014 and notes thereto included in the Company's Form 10-K. The Company follows the same accounting policies in the preparation of interim reports.
	Results of operations for the interim periods are not indicative of annual results.
	The Company has adopted a July 31 year end.
Principles of Consolidation	'
	The consolidated financial statements include the accounts of Altovida, Inc. and Altovida Biosciences Ltd. All significant intercompany balances and transactions have been eliminated. Altovida, Inc. and Altovida Biosciences Ltd will be collectively referred herein to as the “Company”.
Use of Estimates	'
	The preparation of financial statements in accordance with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to stock-based compensation, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Cash and Cash Equivalents	'
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.  At October 31, 2014, the Company had $33,447 in cash and no cash equivalents.
Property and Equipment	'
	Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:
	Equipment 3-5 years
	Furniture 7 years
	The Company reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment there were no impairments needed as of October 31, 2014.
Inventory	'
	Inventories consist of merchandise held for sale in the ordinary course of business, including cost of freight and other miscellaneous acquisition costs, and are stated at the lower of cost, or market value determined on the first-in-first-out basis. The Company records a write-down for inventories, which have become obsolete or are in excess of anticipated demand or net realizable value. The Company performs a detailed review of inventory each period that considers multiple factors including demand forecasts, market conditions, product life cycle status, product development plans and current sales levels. If future demand or market conditions for the Company’s products are less favorable than forecasted or if unforeseen changes negatively affect the utility of the Company’s inventory, it may be required to record additional write-downs, which would negatively affect gross margins in the period when the write-downs are recorded. If actual market conditions are more favorable, the Company may have higher gross margins when products incorporating inventory that were previously written down are sold.
Fair Value of Financial Instruments	'
	Financial instruments consist of cash, inventory, prepaid expenses, accounts payable, and notes payable. Recorded values of these instruments approximate their fair values due to the short-term maturities of such instruments. Recorded values for notes payable and related liabilities approximate fair values, since their stated or imputed interest rates are commensurate with prevailing market rates for similar obligations.
Earnings (Loss) Per Share	'
	The Company reports earnings (loss) per share in accordance with ASC Topic 260-10. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of October 31, 2014, there were no potential common shares underlying warrants or options.
Revenue Recognition	'
	The Company recognized revenue at point of sale of product utilizing the following general revenue recognition criteria: 1) sales order received, and; 2) the price to the buyer is fixed or determinable; and 3) good have been shipped; and 4) collectability is reasonably assured.
Income Taxes	'
	Income taxes are accounted for under the asset and liability method in accordance with ASC Topic 740-10. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When it is considered to be more likely than not that a deferred tax asset will not be realized, a valuation allowance is provided for the excess.
Foreign Currency	'
	The Company accounts for foreign currency in accordance with ASC Topic 830 “Foreign Currency” whereby the local currency is the functional currency. Assets and liabilities of the Company’s foreign locations are translated to reporting currency at the rate of exchange existing at the balance sheet date. Income statement amounts are translated at a weighted average monthly exchange rate for each reporting period. The cumulative translation adjustments resulting from changes in exchange rates are included in the consolidated balance sheet as “Other comprehensive income”, a separate component of stockholders’ equity. Transaction gains and losses are included in the consolidated statement of operations. As of October 31, 2014, the Company recorded $84,350 in translation gains related to foreign currency translation.
New Accounting Standards	'
	On June 10, 2014, the Financial Accounting Standards Board (FASB) issued a new accounting statement that reduces some of disclosures and reporting requirements for development stage companies. The change will be in effect for the interim and annual periods beginning after December 15, 2014. As of such date, among other things development stage entities will no longer be required to report inception-to-date information. The company has elected early adoption of this pronouncement and will no longer being reporting inception-to-date information.
	There are no other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Nature_of_Business_and_Summary2

Nature of Business and Summary of Significant Accounting Policies (Details Narrative) (USD $)	3 Months Ended	11 Months Ended
	Oct. 31, 2014	Oct. 31, 2014	Jul. 31, 2014
Accounting Policies [Abstract]	'	'	'
Date Of Incorporation	15-Jul-11	'	'
Current Fiscal Year End Date	'--07-31	'	'
Cash	$33,447	$33,447	$210,399
Equipment Useful Life Minimum	'3 years	'	'
Equipment Useful Life Maximum	'5 years	'	'
Furniture Useful Life	'7 years	'	'
Foreign currency translation	'	$84,350	'

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	3 Months Ended	11 Months Ended
	Oct. 31, 2014	Oct. 31, 2014
Notes to Financial Statements	'	'
Net loss	($329,955)	($1,103,477)

Business_Combination_Details_N

Business Combination (Details Narrative)	Oct. 31, 2014	Sep. 23, 2014	Jul. 31, 2014	2-May-14
Business Combinations [Abstract]	'	'	'	'
Common Stock, Issued	77,650,166	'	89,930,166	12,280,000
Common Stock, Outstanding	'	'	'	15,050,000
Common Stock, Cancelled	'	12,280,000	'	12,050,000

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	3 Months Ended
	Oct. 31, 2014
Related Party Transactions [Abstract]	'
Agreement effective date	1-Mar-14
Compensation	$167,110

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	3 Months Ended	11 Months Ended
	Oct. 31, 2014	Oct. 31, 2014	Jul. 31, 2014
Forgiveness of Debt	'	$24,000	'
Pinciple Balance	445,000	445,000	445,000
Interest Expense	-6,675	-12,943	'
Knight Finacial	'	'	'
Promissory Note	419,000	419,000	'
Issuance Date	1-May-14	'	'
Principle Amount	81,421	81,421	'
Cash Advance	50,000	'	'
Forgiveness of Debt	24,000	'	'
Interest Rate	6.00%	6.00%	'
Maturity Date	1-May-18	'	'
Pinciple Balance	445,000	445,000	'
Accrued Interest	$12,943	$12,943	'

Stockholders_Deficit_Details_N

Stockholders (Deficit) (Details Narrative) (USD $)	3 Months Ended	11 Months Ended				1 Months Ended
	Oct. 31, 2014	Oct. 31, 2014	Sep. 23, 2014	Jul. 31, 2014	2-May-14	30-May-14	2-May-14	Jun. 20, 2014	Jun. 20, 2014
						Knight Financial, Ltd.	Knight Financial, Ltd.	Chief Executive Officer	Executive Chairman
Common Stock, Shares Authorized	90,000,000	90,000,000	'	90,000,000	'	'	'	'	'
Common Stock, Par Value	$0.00	$0.00	'	$0.00	'	'	$6	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000	'	10,000,000	'	'	'	'	'
Preferred Stock, Par Value	$0.00	$0.00	'	$0.00	'	'	'	'	'
Common Stock, Issued	77,650,166	77,650,166	'	89,930,166	12,280,000	'	69,833	37,325,083	37,325,083
Common Stock, Proceeds	'	$419,000	'	'	'	$419,000	'	'	'
Common Stock, Cancelled	'	'	12,280,000	'	12,050,000	'	5,800,000	5,800,000	'
Subscription Receivable	$64,650	$64,650	'	'	'	'	'	'	'